Altimmune Inc (ALT)
NASDAQ:ALT
Want to see ALT full AI Analyst Report?
ALT Stock Chart & Stats
$3.50
$0.16(2.19%)
At close: 4:00 PM EST
$3.50
$0.16(2.19%)
Day’s Range― - ―
52-Week Range$2.56 - $7.73
Previous CloseN/A
Volume1.55M
Average Volume (3M)3.02M
Market Cap
$548.08M
Enterprise Value$224.04M
Total Cash (Recent Filing)$273.46M
Total Debt (Recent Filing)$35.69M
Price to Earnings (P/E)―
Beta1.56
Next Earnings
May 19, 2026EPS Estimate
-0.24Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.27
Shares Outstanding194,355,180
10 Day Avg. Volume2,166,078
30 Day Avg. Volume3,017,120
Financial Highlights & Ratios
PEG Ratio0.14
Price to Book (P/B)1.41
Price to Sales (P/S)7757.46
P/FCF Ratio-4.71
Enterprise Value/Market Cap0.41
Enterprise Value/Revenue5.46K
Enterprise Value/Gross Profit-15.02
Enterprise Value/Ebitda-2.50
Forecast
1Y Price Target
$11.93Price Target Upside240.86% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering7
EPS Forecast (FY)-1.1
Revenue Forecast (FY)$5.60K
Bulls Say, Bears Say
Bulls Say
Expanded IndicationsProgress in alcohol use disorder and alcohol‑associated liver disease programs could meaningfully expand development and commercial opportunities if upcoming clinical readouts confirm benefit in these underserved indications.
Mechanism Of ActionDual mechanism combining appetite suppression via GLP‑1 activity with direct liver‑fat reduction via glucagon activity could produce superior metabolic and liver outcomes versus GLP‑1‑only therapies, supporting a stronger clinical and commercial case.
Regulatory PathwayRegulatory alignment on key trial parameters together with Breakthrough Therapy Designation creates a clearer path for a pivotal approval program and reduces late‑stage development uncertainty.
Bears Say
Clinical DifferentiationPhase IIb showed therapeutic activity but did not demonstrate clear differentiation from existing treatments, which may hinder the ability to command a premium position in therapy choices.
Competitive LandscapeThe metabolic dysfunction‑associated steatohepatitis market is crowded with established drugs and emerging competitors, increasing pressure on uptake and market share unless the drug shows clear, meaningful advantages.
Development And Financing RiskClinical trial, regulatory, and financing risks introduce substantial uncertainty that could prevent the drug from reaching the market or meeting current valuation expectations.
Altimmune News
ALT FAQ
What was Altimmune Inc’s price range in the past 12 months?
Altimmune Inc lowest stock price was $2.56 and its highest was $7.73 in the past 12 months.
What is Altimmune Inc’s market cap?
Altimmune Inc’s market cap is $548.08M.
When is Altimmune Inc’s upcoming earnings report date?
Altimmune Inc’s upcoming earnings report date is May 19, 2026 which is in 16 days.
How were Altimmune Inc’s earnings last quarter?
Altimmune Inc released its earnings results on Mar 05, 2026. The company reported -$0.27 earnings per share for the quarter, missing the consensus estimate of -$0.234 by -$0.036.
Is Altimmune Inc overvalued?
According to Wall Street analysts Altimmune Inc’s price is currently Undervalued.
Does Altimmune Inc pay dividends?
Altimmune Inc pays a Monthly dividend of $873 which represents an annual dividend yield of N/A. See more information on Altimmune Inc dividends here
What is Altimmune Inc’s EPS estimate?
Altimmune Inc’s EPS estimate is -0.24.
How many shares outstanding does Altimmune Inc have?
Altimmune Inc has 194,355,180 shares outstanding.
What happened to Altimmune Inc’s price movement after its last earnings report?
Altimmune Inc reported an EPS of -$0.27 in its last earnings report, missing expectations of -$0.234. Following the earnings report the stock price went down -17.916%.
Which hedge fund is a major shareholder of Altimmune Inc?
Currently, no hedge funds are holding shares in ALT
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Altimmune Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
$11.93 (240.86% Upside)
$11.93 (240.86% Upside)
Blogger Sentiment
Bullish
ALT Sentiment 75%
Sector Average 72%
Sector Average 72%
Insider Transactions
Bought Shares
Worth $198.1K over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Positive
Last 7 Days ▲ 0.9%
Last 30 Days ▲ 0.5%
Last 30 Days ▲ 0.5%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-23.07%
12-Months-Change
Fundamentals
Return on Equity
-49.35%
Trailing 12-Months
Asset Growth
100.95%
Trailing 12-Months
Company Description
Altimmune Inc
Altimmune, Inc., a clinical stage biopharmaceutical company, focuses on developing treatments for obesity and liver diseases. The company's lead product candidate, pemvidutide (proposed INN, formerly known as ALT-801), is a GLP-1/glucagon dual receptor agonist that is in Phase 1b trial for the treatment of obesity and non-alcoholic steatohepatitis. It is also developing HepTcell, an immunotherapeutic product candidate, which is in Phase 2 clinical trial for patients chronically infected with the hepatitis B virus. The company was formerly known as Vaxin Inc. and changed its name to Altimmune, Inc. in September 2015. Altimmune, Inc. was founded in 1997 is headquartered in Gaithersburg, Maryland.
ALT Earnings Call
Q4 2026
0:00 / 0:00
Earnings Call Sentiment|Positive
The call conveyed a predominantly positive outlook driven by robust Phase II clinical data (early NASH resolution, antifibrotic signals, 7.5% weight loss at 48 weeks), favorable tolerability, FDA Breakthrough designation, clear alignment with the FDA on Phase III design, completed AUD enrollment, and a strengthened balance sheet with a pro forma cash position (~$340M) providing runway into 2028. Key risks discussed included increased near-term operating expenses and G&A, a widened net loss, reliance on biopsy-driven endpoints (NITs not yet registrational), operational and enrollment execution risks for a large global Phase III, and competitive dynamics in the dual-agonist space. On balance, the positives (clinical differentiation, regulatory progress, funding runway, commercial interest) outweigh the challenges, though execution and funding discipline will be critical as Phase III is initiated.View all ALT earnings summariesALT Stock 12 Month Forecast
Average Price Target
$11.93
▲(240.86% Upside)
Technical Analysis
Tvardi Therapeutics
―
Diamedica Therapeutics
―
Alpha Tau Medical Ltd
―
enGene Holdings
―
Lexeo Therapeutics, Inc.
―
Ownership Overview
0.45% Insiders
7.75% Mutual Funds
0.58% Other Institutional Investors
81.30% Public Companies and Individual Investors